An IPO Related Purchase by RA Capital Management – Insider Weekends

Introduction and RA Capital Management Overview

Over time, what we’ve come to realize when writing these Insider Weekends articles is that the insider who is purchasing the shares is equally as important as the company we choose to write about, if not more. There are two key archetypes of insiders we like to look for: founders who remain at the helm of a company as CEO, or independent directors with an investing background. These two types, in some sense, represent opposite ends of the spectrum – founder CEOs are often deep in the weeds of the business. Directors, on the other hand, are a bit removed, which eliminates some level of bias, and their investment background often lets them see the big picture.

But typically, in these articles, we tend to pick a single company and focus equally on both the insider purchasing shares and the business at hand. This week, we figured we’d take a different approach and focus on a single insider instead of a business. Two different purchases by this insider made it into our list of top five insider transactions this week and one of them was a purchase related to a recent IPO.

RA Capital is a Boston-based investment firm that has over 250 employees and over $14 billion in AUM. RA Capital can trace its roots back to 2001, when Richard Aldrich, a co-founder of Vertex Pharmaceuticals (VRTX), began making seed investments in various biotech businesses. He soon hired Peter Kolchinsky, and the firm was officially founded in 2004. Vertex was one of the longest held positions in our model portfolio, which we’ve covered in multiple Insider Weekends articles in the past. We finally exited the position in May 2026, stating the following in our mid-month update:

I am also going to exit one of our oldest positions in the model portfolio, Vertex Pharmaceuticals (VRTX), which has generated gains of 91.76% since we added it to the portfolio on 11/30/2020 following insider purchases by the CEO and Two Briefcase Bruce. I still like the company but it feels like the company is going to see additional competition for its sickle cell disease franchise from Beam Therapeutics (BEAM). Vertex’s non-opioid pain medication is also off to a slower start and investors were not thrilled when the data from the drug was released following Phase 3 trials. I am going to exit the full position both in the model portfolio and in my personal portfolio.

Only plus or premium subscribers can access this post. Subscribe today.